Related references
Note: Only part of the references are listed.OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Carol Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers
Kazuya Kudoh et al.
GYNECOLOGIC ONCOLOGY (2011)
Treatment-Related Mortality With Bevacizumab in Cancer Patients A Meta-analysis
Vishal Ranpura et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Addition of Bevacizumab to Chemotherapy for Treatment of Solid Tumors: Similar Results but Different Conclusions
Alberto Ocana et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Pegylated liposomal doxorubicin combined with carboplatin: A rational treatment choice for advanced ovarian cancer
Sandro Pignata et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2010)
Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: A Gynecologic Oncology Group study
Peter G. Rose et al.
GYNECOLOGIC ONCOLOGY (2010)
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia
Agustin A. Garcia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer
Rakesh K. Jain
NATURE REVIEWS CANCER (2008)
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Robert A. Burger et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Stephen A. Cannistra et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening
Fiona Simpkins et al.
GYNECOLOGIC ONCOLOGY (2007)
Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas
DR D'Adamo et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
AN Gordon et al.
GYNECOLOGIC ONCOLOGY (2004)
Advantages of liposomal delivery systems for anthracyclines
TM Allen et al.
SEMINARS IN ONCOLOGY (2004)
Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer
GJS Rustin et al.
CLINICAL CANCER RESEARCH (2004)
Share Paper
